Login to Your Account

PARIS – Refinement of the EMA's rules for advanced therapy medicinal products (ATMPs), which came into effect in 2009, is ongoing, but, so far at least, there is little evidence to suggest that the legislation has been an enabler for companies developing cell therapies or gene therapies.

DUBLIN – The ongoing delay in appointing a new executive director to the (IMI), Europe’s €3.3 billion (US$2.1 billion) public-private partnership on drug research, shows no immediate signs of ending, while its interim director, EC official Irene Norstedt, has defended the initiative against a major media onslaught.

LONDON – Stock exchanges, private equity firms and venture capitalists are calling for Europe to emulate the U.S. emerging growth company designation to make it easier for small companies to list on public markets, following years of decline in the capital raised through IPOs.
More EUROPE Headlines

Cast Your Vote

Has biotech’s bubble burst?: